Erepdekinra presents a peptide architecture featuring varied residue types that shape solubility, charge distribution, and folding pathways. Researchers examine its structural transitions to assess binding determinants. Its adaptable conformation aids studies of molecular recognition. Applications span ligand-design models, peptide optimization, and structural biochemistry.
CAT No: R2515
CAS No:2641313-47-3
Synonyms/Alias:Erepdekinra;Erepdekinra [INN];UNII-C28VQU7LB4;C28VQU7LB4;2641313-47-3;DA-63256;
Erepdekinra is a recombinant peptide belonging to the interleukin-1 (IL-1) receptor antagonist family, engineered to modulate cytokine signaling pathways in vitro. As a synthetic analog of naturally occurring IL-1 receptor antagonists, it is designed to bind competitively to the IL-1 receptor, thereby inhibiting the biological activity of interleukin-1 alpha and beta. This selective receptor blockade makes Erepdekinra highly relevant for studies exploring inflammatory signaling, immune regulation, and cytokine-mediated cellular responses. Its robust biochemical properties and receptor specificity render it a valuable tool for investigating the molecular mechanisms underlying immune modulation and inflammatory cascades in a controlled research environment.
Inflammatory Pathway Research: Erepdekinra is extensively utilized in the study of inflammatory signaling mechanisms, particularly those mediated by the IL-1 family of cytokines. By competitively inhibiting IL-1 receptor binding, it enables researchers to dissect the downstream effects of IL-1 signaling in various cell types, including immune and stromal cells. This application is critical for unraveling the complex molecular networks that govern inflammation, allowing for precise characterization of cytokine-driven gene expression, signal transduction, and cellular phenotypes in both acute and chronic in vitro models.
Immunological Assays: The compound serves as a potent tool in immunological assays aimed at evaluating cytokine interplay and immune cell activation. Its ability to selectively block IL-1 receptor activation provides a means to differentiate between IL-1-dependent and independent pathways in experimental systems. Researchers leverage Erepdekinra in co-culture assays, cytokine profiling, and immune modulation studies to elucidate the contributions of IL-1 signaling to T cell, macrophage, or dendritic cell function, thereby advancing understanding of immune homeostasis and dysregulation.
Cellular Signaling Pathway Elucidation: Erepdekinra is instrumental in mapping intracellular signaling cascades initiated by IL-1 receptor engagement. By preventing receptor activation, it allows for the isolation and analysis of alternative signaling routes and compensatory pathways. This application is particularly valuable in studies employing transcriptomic, proteomic, or phosphoproteomic approaches, as it facilitates the identification of key mediators and regulatory nodes within the broader cytokine signaling landscape.
Inflammation Model Validation: In vitro models of inflammation often require precise modulation of cytokine activity to validate experimental hypotheses or screen for pathway-specific effects. Erepdekinra is employed to establish negative controls or to attenuate IL-1-driven responses in cellular and organoid systems. Its inclusion in these models supports the differentiation between primary and secondary inflammatory mediators, enhancing the reliability and interpretability of experimental outcomes in inflammation research.
Peptide Functional Studies: As a recombinant peptide, Erepdekinra is also valuable in peptide-based functional analyses, including receptor binding assays and structure-activity relationship investigations. Its defined sequence and receptor specificity make it an ideal reference or comparator in studies assessing novel peptide analogs, engineered cytokine inhibitors, or peptide-receptor interactions. Through these applications, it contributes to the advancement of peptide engineering, therapeutic target validation, and the broader field of cytokine biology research.
2. TMEM16F and dynamins control expansive plasma membrane reservoirs
4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
5. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More